Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
TLX Stock Chart & Stats
AU$8.76
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$8.76
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$8.56 - AU$31.97
Previous CloseN/A
Volume456.62K
Average Volume (3M)2.17M
Market Cap
AU$2.97B
Enterprise ValueAU$3.18B
Total Cash (Recent Filing)AU$207.16M
Total Debt (Recent Filing)AU$418.25M
Price to Earnings (P/E)173.3
Beta1.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding338,777,040
10 Day Avg. Volume3,366,578
30 Day Avg. Volume2,166,331
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)14.35
Price to Sales (P/S)10.41
P/FCF Ratio906.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.89Price Target Upside195.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial MomentumDosing of the BiPASS phase three study in the United States and strong recruitment in Australia could bolster the regulatory case and enable an expanded label for prostate cancer imaging.
Commercial RevenuePre-reported higher total revenue driven by increased diagnostic sales signals strengthening demand for the imaging portfolio and supports revenue momentum.
Regulatory PathwayResubmission of the brain imaging agent Pixclara to the FDA could set a clear path to U.S. regulatory approval and add a new product to the firm's commercial lineup.
Bears Say
Investment RiskAnalyst classification of the investment as high risk highlights elevated uncertainty around clinical, regulatory, and commercial outcomes.
Outcome DependenciesUpside relies on successful regulatory approval, favorable guideline placement, investor willingness to look beyond short-term issues, resolution of safety data and product resubmission, and closure of an ongoing SEC probe without pricing pressure.
Valuation PressureReduced price targets point to tempered valuation expectations and may weigh on investor sentiment toward the stock.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.56 and its highest was AU$31.97 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$2.97B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Currently, no data Available
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,777,040 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.89 (195.51% Upside)
AU$25.89 (195.51% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 94%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.81%
12-Months-Change
Fundamentals
Return on Equity
3.21%
Trailing 12-Months
Asset Growth
138.86%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX Stock 12 Month Forecast
Average Price Target
AU$25.89
▲(195.51% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---